- Page 1/3
- Next Page
COMMENT
Market Outlook There may be some chance the US Fed may reduce interest rates. Although nothing has been said directly, recent comments were taken by the market to suggest a cut would be more likely than a rate hike. In the last month, the risk of rising trade war with China has increased. There seems to be a rotation toward defensive stocks. Try not to get distracted by the noise in the market. Now is not the time to bet big on a single investment strategy -- wait to see if growth will continue. Sometimes it is best to do nothing.
WAIT
Is is involved in advertising technology. They have 20-30% growth in sales, but you are paying 60 times earnings. He suspects news of greater regulation for privacy will be a tail wind. If the macro economic background becomes negative, this could take a big hit. Keep it on the radar, but not a time to buy.
HOLD
It is very similar to Amazon -- a leader in global internet commerce. You are paying for a sustainable growth at a reasonable price. It has had some negative revisions, but this is clearing the deck for going forward.
0
COMMENT
Technical outlook? The Ag space has a close following of technical traders. It is hard to be on a level playing field, playing against professional traders. The stock has been pretty range bound, so it does not check the technical boxes for them to get too excited about it. He would suggest playing the space with an ETF instead.
agriculture
COMMENT
Pending investigation? The likely regulation of privacy concerns is impacting this space, led by Facebook. This has been coming for a while and it may likely continue to dog these stocks, especially if this becomes politicized. If President Trump decides to make an issue of this, it could become real trouble. He would back away if this is the direction things go. Be very careful. He loves the company and they are doing things correctly. It is just not clear to him if this is the time to reenter.
Technology
COMMENT
Lawsuit impacts? It is facing a lawsuit on talcum powder impact on babies. These type of lawsuits can be dragged out and become an uphill battle for the company. Since this does not represent a major portion of the revenues, it should not be a long term influence. The risk is the market will redetermine the correct trading multiple and that is hard to predict. He would rather trade a medical device ETF, that includes JNJ-N.
biotechnology
pharmaceutical
HOLD
It yields around 7%. This requires a call on Europe. It has been recovering reasonably well since the new year. Germany has rebounded well, but there are some auto tariff uncertainties. Technically, it has been showing some support. As long as a recession is not forthcoming, it could be a good yield play.
E.T.F.'s
COMMENT
Downside protection? They have a technical process, but it may be a little unclear if that is best in this space. Sometimes fundamentals are very critical. He uses technicals more to confirm a position -- especially to know when to be kicked out to limit downside exposure. It has not traded very long, so it may be too early to jump in.
E.T.F.'s
DON'T BUY
They finally had a quarter that beat expectations on earnings and revenues. It is hard to quantify when this make sense to own it again. Those who bought it on the way day will create a mountain of selling on the way back up. Fundamentally, the changes management needs to make will take a long time. He would stay away.
electrical
electronic
WAIT
Software earnings have been doing well. They beat out on gross margins and have taken on steps to help mitigate tariff issues. Can they continue to avoid issues on the hardware side if tariff issues escalate? He thinks not. A well managed company, but he really worries about further tariff issues. He would wait until these issues resolve themselves.
electrical
electronic
